7.41
price down icon3.26%   -0.25
pre-market  Vorhandelsmarkt:  7.01   -0.40   -5.40%
loading
Schlusskurs vom Vortag:
$7.66
Offen:
$7.66
24-Stunden-Volumen:
122.76K
Relative Volume:
1.11
Marktkapitalisierung:
$403.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.01%
1M Leistung:
-15.99%
6M Leistung:
-40.72%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$7.24
$7.74
1-Wochen-Bereich:
Value
$7.24
$7.89
52-Wochen-Spanne:
Value
$6.75
$13.50

Alumis Inc Stock (ALMS) Company Profile

Name
Firmenname
Alumis Inc
Name
Telefon
650-231-6625
Name
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Mitarbeiter
147
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ALMS's Discussions on Twitter

Vergleichen Sie ALMS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALMS
Alumis Inc
7.41 403.16M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-31 Eingeleitet Robert W. Baird Outperform
2024-10-17 Eingeleitet H.C. Wainwright Buy
2024-07-23 Eingeleitet Cantor Fitzgerald Overweight
2024-07-23 Eingeleitet Guggenheim Buy
2024-07-23 Eingeleitet Leerink Partners Outperform
2024-07-23 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Alumis Inc Aktie (ALMS) Neueste Nachrichten

pulisher
Jan 20, 2025

How To Trade (ALMS) - Stock Traders Daily

Jan 20, 2025
pulisher
Jan 17, 2025

JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

Jan 17, 2025
pulisher
Jan 09, 2025

Where are the Opportunities in (ALMS) - Stock Traders Daily

Jan 09, 2025
pulisher
Jan 07, 2025

Barclays PLC Has $230,000 Holdings in Bel Fuse Inc. (NASDAQ:BELFA) - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Principal Financial Group Inc. Invests $289,000 in iShares MBS ETF (NASDAQ:MBB) - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Jane Street Group LLC Grows Stock Position in Pangaea Logistics Solutions, Ltd. (NASDAQ:PANL) - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Alumis’ (ALMS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Geode Capital Management LLC Purchases Shares of 305,680 Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Barclays PLC Buys Shares of 18,360 Alumis Inc. (NASDAQ:ALMS) - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

UWM Holdings Co. (NYSE:UWMC) Shares Bought by Barclays PLC - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Alumis (NASDAQ:ALMS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

H.C. Wainwright reaffirms Buy rating on Alumis stock following Bristol-Myer's PsA data - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Piedmont Lithium Inc. (NASDAQ:PLL) Given Average Recommendation of “Hold” by Analysts - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

State Street Corp Makes New Investment in Alumis Inc. (NASDAQ:ALMS) - Defense World

Jan 03, 2025
pulisher
Jan 03, 2025

State Street Corp Purchases Shares of 81,059 Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Jan 03, 2025
pulisher
Dec 31, 2024

hedge funds investors of Alumis Inc. (NASDAQ:ALMS) must be disappointed after last week's 10% drop - Simply Wall St

Dec 31, 2024
pulisher
Dec 31, 2024

Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Brokerages - Defense World

Dec 31, 2024
pulisher
Dec 28, 2024

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS), - Yahoo Finance

Dec 28, 2024
pulisher
Dec 24, 2024

Stifel Financial Corp Invests $931,000 in Alumis Inc. (NASDAQ:ALMS) - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Stifel Financial Corp Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Dec 24, 2024
pulisher
Dec 23, 2024

Alumis’ (ALMS) “Buy” Rating Reiterated at HC Wainwright - Defense World

Dec 23, 2024
pulisher
Dec 21, 2024

BNP Paribas Financial Markets Buys New Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor - Yahoo! Voices

Dec 20, 2024
pulisher
Dec 20, 2024

Alumis (NASDAQ:ALMS) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Alumis reports promising Phase 1 trial results for MS drug - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Alumis reports promising Phase 1 trial results for MS drug By Investing.com - Investing.com South Africa

Dec 19, 2024
pulisher
Dec 19, 2024

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - The Manila Times

Dec 19, 2024
pulisher
Dec 19, 2024

Alumis Reports Breakthrough Clinical Data: TYK2 Drug Shows Strong Brain Penetration in Phase 1 Trial - StockTitan

Dec 19, 2024
pulisher
Dec 18, 2024

Charles Schwab Investment Management Inc. Takes $1.16 Million Position in Alumis Inc. (NASDAQ:ALMS) - Defense World

Dec 18, 2024
pulisher
Dec 18, 2024

Charles Schwab Investment Management Inc. Invests $1.16 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To Expire on December 25th - Defense World

Dec 18, 2024
pulisher
Dec 18, 2024

Alumis Inc.'s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th - MarketBeat

Dec 18, 2024
pulisher
Dec 13, 2024

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

Dec 13, 2024
pulisher
Dec 13, 2024

Pre-market Movers: LOOP, RPTX, CADL, INO, ISPC… - RTTNews

Dec 13, 2024
pulisher
Dec 09, 2024

(ALMS) Technical Data - Stock Traders Daily

Dec 09, 2024
pulisher
Dec 06, 2024

Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Samsara BioCapital LLC Acquires Shares of 3,266,498 Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Dec 05, 2024
pulisher
Dec 03, 2024

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Quantisnow

Dec 03, 2024
pulisher
Nov 28, 2024

How the (ALMS) price action is used to our Advantage - Stock Traders Daily

Nov 28, 2024
pulisher
Nov 28, 2024

Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow

Nov 28, 2024
pulisher
Nov 28, 2024

Ally Bridge Group NY LLC Cuts Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat

Nov 28, 2024
pulisher
Nov 28, 2024

Alumis: A Best-In-Class TYK2 Inhibitor (NASDAQ:ALMS) - Seeking Alpha

Nov 28, 2024
pulisher
Nov 25, 2024

Alumis updates clinical trial dates for lupus study By Investing.com - Investing.com Australia

Nov 25, 2024
pulisher
Nov 25, 2024

Alumis updates clinical trial dates for lupus study - Investing.com

Nov 25, 2024
pulisher
Nov 21, 2024

Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN

Nov 21, 2024
pulisher
Nov 19, 2024

Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online

Nov 19, 2024
pulisher
Nov 18, 2024

What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $26.00 - Defense World

Nov 16, 2024
pulisher
Nov 14, 2024

Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times

Nov 14, 2024

Finanzdaten der Alumis Inc-Aktie (ALMS)

Es liegen keine Finanzdaten für Alumis Inc (ALMS) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alumis Inc-Aktie (ALMS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Foresite Capital Management V,
10% Owner
Jul 01 '24
Buy
16.00
2,500,000
40,000,000
5,584,889
Tananbaum James B.
Director
Jul 01 '24
Buy
16.00
2,500,000
40,000,000
5,584,889
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Kapitalisierung:     |  Volumen (24h):